SMALL INTESTINE: Edited by Reena SidhuAdvances in chronic intestinal failure management and therapiesDeutsch, Liata; Cloutier, Anabelleb; Lal, Simonb,cAuthor Information aThe Department of Gastroenterology and Liver diseases, Tel-Aviv Sourasky Medical Centre and Sackler Faculty of Medicine, Tel-Aviv University, Israel bIntestinal Failure Unit, Salford Royal NHS Foundation Trust, Salford cManchester Academic Health Sciences Centre, University of Manchester, Manchester, UK Correspondence to Liat Deutsch, MD, Department of Gastroenterology and Liver diseases, Tel-Aviv Sourasky Medical Centre, 6 Weizmann Street, Tel Aviv 6423906, Israel. Tel: +972 3 6974119; fax: +972 3 6973422; e-mail: Liatml@tlvmc.gov.il Current Opinion in Gastroenterology: May 2020 - Volume 36 - Issue 3 - p 223-229 doi: 10.1097/MOG.0000000000000631 Buy Metrics Abstract Purpose of review To summarize changes and recent advances in therapies for chronic intestinal failure (CIF). Recent findings In the last few years, the management of CIF has significantly improved through better prevention and treatment of catheter-related bloodstream infections (CRBSIs) and intestinal failure-associated liver disease (IFALD), as well as improved enteral autonomy by using small bowel growth factors in selected patients. This may have been reflected by a recent reduction in small bowel transplantations. Summary Although CIF management has become more established and effective, the long-term implications of parenteral nutrition still place substantial burden on patients such that further work is required to improve patients’ quality of life as well as continued efforts to reduce complications relating to CIF management. Copyright © 2020 Wolters Kluwer Health, Inc. All rights reserved.